Researchers at Northwestern Medicine have identified immune system markers that may help predict who responds to BCG bladder cancer therapy and who does not, according to findings published in the Journal of Clinical Investigation. The study focuses on understanding why some patients with non-muscle invasive bladder cancer benefit from Bacillus Calmette-Guérin (BCG) immunotherapy while others do not, a longstanding challenge in oncology.
Bladder cancer is one of the most common cancers worldwide, and BCG therapy has been the standard of care for high-risk non-muscle invasive bladder cancer for decades. However, up to 40% of patients do not respond to treatment, and there are currently no reliable biomarkers to predict response. The Northwestern team analyzed tumor samples and blood from patients undergoing BCG therapy and identified specific immune cell signatures associated with treatment success. These biomarkers could allow clinicians to tailor therapy, potentially sparing non-responders from ineffective treatments and their side effects.
The findings are significant because they offer a pathway toward personalized medicine in bladder cancer. If validated in larger trials, these biomarkers could be integrated into clinical practice, guiding decisions on whether to continue BCG or switch to alternative therapies such as checkpoint inhibitors or novel immunotherapies. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also working to refine immunotherapy approaches, highlighting the growing interest in leveraging the immune system against cancer.
The research underscores the broader trend of using immune profiling to improve cancer treatment. As the field moves toward precision oncology, identifying predictive biomarkers is crucial for optimizing outcomes. The Northwestern team plans to conduct prospective studies to confirm the clinical utility of these markers.
For patients, this research offers hope that future treatment decisions will be based on biological insights rather than trial and error. The study adds to a growing body of evidence that the immune system plays a central role in bladder cancer response, opening doors for combination therapies and new drug development.
